Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Canada bars return of Pfizer drug
Pfizer voluntarily pulled Bextra from the Canadian market in April 2005 upon the request of Health Canada. Despite disagreeing with the regulators position on the risk/benefit profile of
Pfizer voluntarily pulled Bextra from the Canadian market in April 2005 upon the request of Health Canada. Despite disagreeing with the regulators position on the risk/benefit profile of
Animas is expected to operate as a stand-alone entity reporting through LifeScan, a Johnson & Johnson company offering blood glucose monitoring systems. The acquisition affords LifeScan immediate entry
The decision follows a review of data including the clinical, scientific, and epidemiological data establishing the safety and efficacy of the vaccine. “This decisive ruling marks an important
Interim findings following 24 weeks of dosing demonstrated potent antiviral activity for brecanavir in both PI-sensitive and PI-resistant HIV-infected adults. These data were presented at the 45th Interscience
Patients enrolled in the study, being conducted at two sites in the UK, will receive three months treatment with each of three different therapies – Bronchitol alone, both
The positive results from the trials bring the drug a step closer to a regulatory filing for marketing approval. The studies met their primary endpoints and showed that
Under terms of the agreement, AlgoRx stockholders own approximately 62% of the combined company on a pro forma basis and Corgentech stockholders own approximately 38%. The completion of
Under the agreement, scientists at AstraZeneca R&D will access Eidogen-Sertanty’s target informatics platform (TIP) and EVE comparative visualization software to assist drug discovery efforts within their cancer and
CTCE-0214 is designed to trigger trafficking of immune system cells and stem cells, as well as regeneration of white blood cells and platelets. The company hopes that the
The new company, to be called Cyclacel Pharmaceuticals, will have two clinical stage, mechanism-targeted, small molecule drug candidates in cancer, a third candidate expected to enter clinical trials